A randomized controlled trial of transcranial magnetic stimulation and enhanced external counter pulsation to improve hand function after ischemic stroke

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14005009

Enrollment

Unknown

Registered

2014-07-25

Start date

2014-09-20

Completion date

Unknown

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Two grous:Device transcranial magnetic stimulation & enhanced external conterpulsation 10 sessions for TBS and EECP versus 10 sessions of sham therapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) patients aged 18 or above; 2) first-ever ischemic subcortical stroke with onset time less than 21 days; 3) hand weakness (distal MRC 1- 5-) as a result of stroke; 4) recordable MEPs over ipsilesional hemisphere; 5) intracranial hemorrhage excluded by brain computed tomography (CT) / magnetic resonance imaging (MRI); 6) the patient or his/her legally acceptable representative is willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: For TMS : 1) personal history of epilepsy; 2) metallic implants in any part of body; 3) implanted cardiac pacemaker, defibrillator, medication pump or any other implanted electronics; 4) severe skull fracture, serious head injury, history of brain or spinal cord surgery; 5) brain tumour or other significant non-ischemic brain lesion on CT/MRI; 6) administration of drugs that potentially lower seizure threshold; 7) active malignancy; 8) severe co-existing systemic diseases: eg. renal failure (creatinine more than 300 umol/L, if known), cirrhosis, severe dementia or psychosis; 9) inability to be followed up at regular interval; 10) pegnancy or breast-feeding. For ECP: 11) evidence for cardioembolic stroke such as atrial fibrillation and rheumatic heart disease; 12) sustained hypertension (systolic higher than 180mmHg or diastolic higher than 100mmHg); 13) subject has thrombocytopenia (platelet count less than 100,000/mm3); 14) evidence of arteriovenous malformation, arteriovenous fistula or aneurysm; 15) evidence of diabetic retinopathy.

Design outcomes

Primary

Measure	Time frame
upper limb Fugl-Meyer Assessment (FMA);	—

Secondary

Measure	Time frame
FMA, National Institutes of Health Stroke Scale (NIHSS), modified-Rankin Scale (mRS);;grip strength, lateral pinch grip, purdue pegboard test;;TMS measures including RMT, AMT, MEPs;	—

Countries

China

Contacts

Public ContactKa Sing WONG

Division of Neurology, Dept of Medicine and Therapeutics, PWH

ks-wong@cuhk.edu.hk+852 2632 3877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026